According to the latest report by IMARC Group, titled “Hydroxychloroquine Market Size : Global Industry Trends, Share, Opportunity and Forecast 2021-2026,”The global hydroxychloroquine market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to exhibit robust growth during 2021-2026.
Hydroxychloroquine (HCQ) is a derivative of chloroquine that is primarily used to treat or prevent malaria. It is also used in the treatment of numerous autoimmune diseases, such as systemic and discoid lupus erythematosus and rheumatoid arthritis. It exhibits endothelial stabilizing and anti-thrombotic effects as it containsantigens and cytokines.
Base Year: 2020
Forecast Year: 2021-2026
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Global Hydroxychloroquine Market Trends:
The global market is majorly driven by the outbreak of the COVID-19 pandemic across the globe. Hydroxychloroquine has gained widespread prominence due to its effectiveness inthe treatmentof COVID-19 patients, thereby providing an impetus to the market growth. Furthermore, the increasing prevalence of malaria and other chronic disorders is providing a thrust to the market growth. Along with this, the rapidly rising cases of autoimmune diseases,and the escalating demand for generic drugs are further providing an impetus to the market growth. Other factors, including increasing investments by the governments of several countries to improve the overall healthcareinfrastructure and extensive research and development (R&D) activities, are also projected to drive the market growth
Request Free Sample Report: https://www.imarcgroup.com/hydroxychloroquine-market/requestsample
Global Hydroxychloroquine Market 2021-2026 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Amneal Pharmaceuticals Inc., Cardinal Health Inc., Cipla Ltd., Ipca Laboratories Ltd., Laurus Labs, Lupin Limited, Mylan N.V., Novartis AG, Prasco Laboratories, Dr. Reddy’s Laboratories Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Torrent Pharma, Zydus Cadila, etc.
The report has segmented the market on the basis on type, region, distribution, application,grade and administration
Breakup by Dosage Type:
- 200 Mg
- 300 Mg
- 400 Mg
Breakup by Distribution:
- Hospital Pharmacies
- Retail Pharmacies
Breakup by Application:
- Rheumatoid Arthritis
- Lupus Erythematosus
- Coronavirus (COVID-19)
Breakup by Grade:
- USP Standards Grade
- EP Standards Grade
- Pharmaceutical Standards Grade
Breakup by Route of Administration:
Breakup by Region:
- North America
- United States
- Asia Pacific
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://bit.ly/3I9K0EZ
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Group 30 N Gould St Ste R Sheridan, WY 82801 USA – Wyoming Email: Sales@imarcgroup.com Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800